EuBiologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
EuBiologics makes vaccines and biological medicines designed to prevent or treat infectious diseases.
Its products are supplied to public-health programs and medical institutions. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. Because the filing text provided does not detail specific product lines or structural arrangements, only the company's general role as a biologics developer can be confirmed.
Summary is AI-generated and may contain errors · figures from DART filings
EuBiologics in five facts
What does EuBiologics do?
EuBiologics makes vaccines and biological medicines designed to prevent or treat infectious diseases.
Where is EuBiologics listed and in which sector?
EuBiologics (Korean name: 유바이오로직스) trades under KRX code 206650 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is EuBiologics?
Its market capitalisation was US$215.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were EuBiologics's latest annual revenue and operating profit?
For fiscal year 2025, EuBiologics reported revenue of US$112.6M, operating profit of US$45.8M and net income of US$31.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 55.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 21
- DisclosureOct 21
- DisclosureOct 6
- [Amended] Decision to acquire shares/equity in another company
EuBiologics updated the disclosed terms of an acquisition, now worth US$10.7M.
M&A · Aug 26 - [Amended] Supply contract signed (voluntary)
EuBiologics updated a previously disclosed supply contract with UNICEF, now worth US$6.83M, about 6.77% of its recent annual revenue, running through Dec 2026.
Supply contract · Jul 16 - Supply contract signed (voluntary)
EuBiologics disclosed a supply contract with UNICEF, worth US$6.79M, about 6.77% of its recent annual revenue, running through Sep 2026.
Supply contract · Jul 14 - Supply contract signed
EuBiologics disclosed a supply contract with UNICEF, worth US$19.7M, about 19.97% of its recent annual revenue, running through Aug 2026.
Supply contract · Jun 16 - Supply contract signed (voluntary)
EuBiologics disclosed a supply contract with UNICEF, worth US$8.65M, about 8.89% of its recent annual revenue, running through Aug 2026.
Supply contract · Jun 5 - Supply contract signed (voluntary)
EuBiologics disclosed a supply contract with UNICEF, worth US$5.64M, about 5.7% of its recent annual revenue, running through Jul 2026.
Supply contract · May 19 - [Amended] Decision to acquire shares/equity in another company
EuBiologics updated the disclosed terms of an acquisition, now worth US$10.1M.
M&A · Apr 22 - Decision to acquire shares/equity in another company
EuBiologics disclosed an acquisition, worth US$9.9M.
M&A · Mar 26 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
EuBiologics reported separate results for FY2025: revenue of US$103M (+55.4% year on year), operating profit of US$41.9M (+76.8% year on year) and net income of US$33.6M (+156.4% year on year).
Earnings · Feb 2 - Supply contract signed (voluntary)Supply contract · Jan 23